Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pluri Inc. (PLUR : NSDQ)

• Company Description    Pluri Inc. is a biotechnology company. Its technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of medicine and climate change to food scarcity, animal cruelty and beyond. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is based in HAIFA, Israel. Number of Employees: 113

• Price / Volume Information    Yesterday's Closing Price: $0.99 Daily Weekly Monthly 20 Day Moving Average: 14,819 shares Shares Outstanding: 12.61 (millions) Market Capitalization: $12.48 (millions) Beta: 0.69 52 Week High: $4.87 52 Week Low: $0.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.71% -4.72% 12 Week -36.54% -38.09% Year To Date -66.89% -69.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 - HAIFA,L3 3508409 ISR ph: 972-74-710-8600 fax: 972-74-710-8787 investor.relations@pluristem.com https://pluri-biotech.com

• General Corporate Information    Officers Yaky Yanay - Chief Executive Officer and President Alexandre Weinstein - Chairman Liat Zalts - Chief Financial Officer and Treasurer Rami Levi - Director Doron Shorrer - Director Peer Information Pluri Inc. (CORR.) Pluri Inc. (RSPI) Pluri Inc. (CGXP) Pluri Inc. (BGEN) Pluri Inc. (GTBP) Pluri Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 72942G203 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 12.61 Most Recent Split Date: 4.00 (0.13:1) Beta: 0.69 Market Capitalization: $12.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 12.29 EPS Growth vs. Year Ago Period: 79.39% vs. Previous Quarter: 1.82% Sales Growth vs. Year Ago Period: -63.15% vs. Previous Quarter: 100.60% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - -82.71 03/31/26 - -106.59 Current Ratio 09/30/26 - - 06/30/26 - 0.27 03/31/26 - 0.33 Quick Ratio 09/30/26 - - 06/30/26 - 0.27 03/31/26 - 0.33 Operating Margin 09/30/26 - - 06/30/26 - -2,344.59 03/31/26 - -2,162.08 Net Margin 09/30/26 - - 06/30/26 - -2,344.59 03/31/26 - -2,162.08 Pre-Tax Margin 09/30/26 - - 06/30/26 - -2,499.41 03/31/26 - -1,696.48 Book Value 09/30/26 - - 06/30/26 - -1.62 03/31/26 - -1.21 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©